'); } else { var query = elem.find('.keywords').html(); $.ajax({ context: elem, url: 'https://wn.com/api/upge/cheetah-search-adv/video', cache: true, data: { 'query': query }, dataType: 'jsonp', success: function(text) { if (text.length > 0) { video_id = text[0].id; elem.find('.player').html(''); } } }); } } var stopAllYouTubeVideos = function() { var iframes = document.querySelectorAll('iframe'); Array.prototype.forEach.call(iframes, function(iframe) { iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*'); }); } jQuery(function() { jQuery(".playVideo").live("click", function() { if(!$(this).hasClass("played")){ stopAllYouTubeVideos(); var elem = $(this); setTimeout(function(){ mouseOverMe(elem); }, 1000); } }); jQuery(".description_box .expandContent").live("click", function() { elem = $(this).parent().parent().parent().find('.descContent'); if(elem.height() > 51) { elem.css('height', '44px'); $(this).html('Show More '); }else{ elem.css('height', 'auto'); $(this).html('Hide '); } }); jQuery('.interview-play-off').click(function() { $(".interview-play-off").hide(); $(".interview-play").show(); $(".videoplayer-control-pause").click(); }); jQuery(".video-desc .show_author_videos").live("click", function() { query = $(this).attr('title'); container = $(this).parent().parent().parent().find('.video-author-thumbs'); $(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px'); jQuery.ajax({ url: '/api/upge/cheetah-photo-search/videoresults', data: {'query': query}, success: function(text) { if(!text) { text = i18n("No results"); } container.html(jQuery(text)); } }); }); }); // -->

Latest News for: inhibitor

Edit

Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

PR Newswire 30 Mar 2026
"Our lead DNA pol IIIC inhibitor, ibezapolstat, is ready to advance to international, Phase 3, pivotal registration trials in the US and EU for oral treatment of acute C.
Edit

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma

PR Newswire 30 Mar 2026
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor) ... In addition, IDE849 is being evaluated in a clinical combination with IDEAYA's potential first-in-class Phase 1 PARG inhibitor, IDE161.
Edit

TGFB Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook

GetNews 27 Mar 2026
DelveInsight’s, “Transforming Growth Factor Beta Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Transforming Growth Factor Beta Inhibitors pipeline landscape.
Edit

TIGIT Inhibitor Clinical Pipeline Strengthens as 14+ Companies Advance 18+ Novel Immunotherapy Candidates | DelveInsight

GetNews 27 Mar 2026
"TIGIT Inhibitor Clinical Trial" ... DelveInsight’s latest report, “,” provides a comprehensive analysis of the rapidly evolving TIGIT inhibitor landscape ... Emerging Drug Profiles in the TIGIT Inhibitor Space ... TIGIT Inhibitors.
Edit

TIGIT Inhibitor Clinical Trial Pipeline Gains Momentum: 14+ Companies Lead the Charge in Pioneering New ...

GetNews 27 Mar 2026
Inactive Products TIGIT Inhibitors Key Companies TIGIT Inhibitors Key Products TIGIT Inhibitors- Unmet Needs TIGIT Inhibitors- Market Drivers and Barriers TIGIT Inhibitors- Future Perspectives and ...
Edit

CDK 12 Inhibitor Clinical Trial Pipeline Accelerates as 3+ Pharma Companies Rigorously Develop Drugs for ...

GetNews 27 Mar 2026
Inactive Products CDK12 Inhibitor Key Companies CDK12 Inhibitor Key Products CDK12 Inhibitor- Unmet Needs CDK12 Inhibitor- Market Drivers and Barriers CDK12 Inhibitor- Future Perspectives and ...
Edit

Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, ROA, Molecules, Companies and Future Outlook

GetNews 27 Mar 2026
CBP 501 Early Stage Products (Phase I) OncoC4 ONC-841 Preclinical and Discovery Stage Products Company Name Product Name Inactive Products Checkpoint Inhibitors- Unmet needs Checkpoint Inhibitors – Market drivers and barriers Appendix.
Edit

PD-1 and PD-L1 Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook

GetNews 27 Mar 2026
DelveInsight’s “PD-1 and PD-L1 Inhibitors Competitive landscape 2026” report provides comprehensive insights about 180+ companies and 200+ drugs in the PD-1 and PD-L1 Inhibitors Competitive landscape.
Edit

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in ...

Nasdaq Globe Newswire 26 Mar 2026
Agomab today announced that the USPTO granted a patent covering the composition of matter of AGMB-447 ... .
Edit

PARP Inhibitor Clinical Pipeline Demonstrates Strong Momentum with 30+ Companies Advancing Innovative Therapies | DelveInsight

GetNews 26 Mar 2026
"PARP Inhibitor Pipeline Insight". Leading PARP Inhibitor companies driving innovation in this space include TESARO, AstraZeneca, Sun BioPharma, Eisai Co., BeiGene, IMPACT Therapeutics, and Ribon Therapeutics, among others ... Overview of PARP Inhibitors.
×